Passage Bio, a clinical-stage genetic medicines company dedicated to improving the lives of patients with neurodegenerative diseases, will present at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be led by Will Chou, M.D., President and CEO of Passage Bio, on Monday, September 9th at 7:00 a.m. ET. The event will be broadcast live on Passage Bio’s website, and a recording will be available for 30 days following the event. Passage Bio’s lead product candidate, PBFT02, aims to treat neurodegenerative conditions like frontotemporal dementia by increasing progranulin levels to restore lysosomal function and slow disease progression.